Accéder au contenu
Merck

Targeting the prostaglandin F2α receptor for preventing preterm labor with azapeptide tocolytics.

Journal of medicinal chemistry (2011-07-22)
Carine B Bourguet, Eugénie Goupil, Danaë Tassy, Xin Hou, Eryk Thouin, Felix Polyak, Terence E Hébert, Audrey Claing, Stéphane A Laporte, Sylvain Chemtob, William D Lubell
RÉSUMÉ

The prostaglandin-F2α (PGF2α) receptor (FP) was targeted to develop tocolytic agents for inhibiting preterm labor. Azabicycloalkane and azapeptide mimics 2-10 were synthesized based on the (3S,6S,9S)-indolizidin-2-one amino acid analogue PDC113.824 (1), which was shown to modulate FP by a biased allosteric mechanism, involving both Gαq- and Gα12-mediated signaling pathways, and exhibited significant tocolytic activity delaying preterm labor in a mouse model ( Goupil ; et al. J. Biol. Chem. 2010 , 285 , 25624 - 25636 ). Although changes in azabicycloalkane stereochemistry and ring size caused loss of activity, replacement of the indolizidin-2-one amino acid with azaGly-Pro and azaPhe-Pro gave azapeptides 6 and 8, which reduced PGF2α-induced myometrial contractions, potentiated the effect of PGF2α on Gαq-mediated ERK1/2 activation, and inhibited FP modulation of cell ruffling, a response dependent on the Gα12/RhoA/ROCK signaling pathway. Revealing complementarities of azabicycloalkane and azapeptide mimics, novel probes, and efficient tocolytic agents were made to study allosteric modulation of the FP receptor.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hydroxylamine hydrochloride, 99.999% trace metals basis
Sigma-Aldrich
Hydroxylamine hydrochloride, 99.995% trace metals basis